Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GC33

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Introduction: Codrituzumab/GC33/RO5137382 (GC33) is a humanized monoclonal antibody that targets glypican-3 (GPC3), an oncofetal… Expand
Is this relevant?
2014
2014
GC33 is a humanized mAb against human glypican-3 (GPC3). In the first-in-human study carried out in the USA, GC33 was well… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
4100 Background: GC33 is a recombinant humanized monoclonal antibody against Glypican-3 (GPC3) which is highly expressed in HCC… Expand
Is this relevant?
2014
2014
e15090 Background: Glypican-3 (GPC3) is an oncofetal protein frequently expressed in HCC. GC33 is a humanized monoclonal antibody… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Purpose: GC33 is a novel recombinant fully humanized monoclonal antibody that binds to human glypican-3 (GPC3). The antitumor… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 1
Is this relevant?
2013
2013
235 Background: Glypican-3 (GPC3) belongs to a family of cell-surface heparan sulfate proteoglycans and is specifically expressed… Expand
Is this relevant?
2011
2011
4085 Background: Glypican 3 (GPC3) belongs to a family of cell-surface heparan sulfate proteoglycans and is specifically… Expand
Is this relevant?
2010
2010
Glypican 3 (GPC3), a glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan, is expressed in a majority of… Expand
Is this relevant?
2009
2009
Previously, we demonstrated the antitumor efficacy of the anti-glypican-3 (GPC3) antibody GC33 in several human liver cancer… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Human glypican 3 (GPC3) is preferentially expressed in the tumor tissues of liver cancer patients. In this study, we obtained a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?